Catestatin and Diabetic Retinopathy in Type 2 Diabetes Mellitus

<b>Background:</b> Diabetic retinopathy (DR) is the most common microvascular complication of type 2 diabetes mellitus (T2DM). Catestatin (CST) has been implicated in cardiovascular physiology and autonomic modulation, but its role in diabetic microvascular disease remains unclear. <b>Methods:</b> In this cross-sectional study, serum CST levels were compared between healthy controls (<i>n</i> = 59) and patients with T2DM (<i>n</i> = 91), and further between T2DM patients with (<i>n</i> = 63) and without DR (<i>n</i> = 28). <b>Results:</b> CST levels did not differ between T2DM and healthy controls (16 vs. 14 ng/mL; <i>p</i> = 0.693). Among normotensive individuals, healthy controls had the lowest CST levels (6 ng/mL), whereas normotensive T2DM participants showed significantly higher concentrations (11 ng/mL; <i>p</i> = 0.004). Participants with DR exhibited significantly higher CST than those without DR (14 vs. 10 ng/mL; <i>p</i> = 0.034). In the total cohort, arterial hypertension (AH) was the strongest independent predictor of CST (B = 0.562; <i>p</i> < 0.001). In the multivariable model restricted to T2DM patients, DR emerged as the sole independent determinant of CST (B = 0.251; <i>p</i> = 0.028), whereas AH was no longer significant (<i>p</i> = 0.581). <b>Conclusions:</b> Circulating catestatin levels were not associated with the presence of T2DM itself but were significantly elevated in patients with DR. These findings suggest that CST may reflect microvascular and neurovascular stress rather than metabolic status and could represent a biomarker of diabetic microangiopathy.